Covered recipient · General Payments record
SUZANNE E CUDA
Allopathic & Osteopathic Physicians Pediatrics Obesity Medicine
General Payments · PY2019–2024
$39,727.28
- Reported across 95 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $5,000.00 | 2 |
| Food and Beverage | $430.94 | 9 |
| Education | $225.89 | 7 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| VIVUS LLC | $5,089.76 | 3 |
| Novo Nordisk AS | $426.39 | 12 |
| Itamar Medical Inc | $94.97 | 1 |
| Rhythm Pharmaceuticals, Inc. | $45.71 | 2 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (18)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Itamar Medical Inc | $94.97 | 01/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1154006556 | CMS |
| Novo Nordisk Inc | $0.09 | 02/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096575031 | CMS |
| Novo Nordisk Inc | $14.42 | 02/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097351635 | CMS |
| Novo Nordisk Inc | $104.97 | 02/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097343849 | CMS |
| Novo Nordisk Inc | $62.45 | 04/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097149994 | CMS |
| Novo Nordisk Inc | $18.57 | 05/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096691947 | CMS |
| Novo Nordisk Inc | $32.27 | 09/16/2024 | Education | Undisputed | 01/23/2026 | 1096862040 | CMS |
| Novo Nordisk Inc | $32.27 | 09/16/2024 | Education | Undisputed | 01/23/2026 | 1096917208 | CMS |
| Novo Nordisk Inc | $32.27 | 09/16/2024 | Education | Undisputed | 01/23/2026 | 1097053740 | CMS |
| Novo Nordisk Inc | $32.27 | 09/16/2024 | Education | Undisputed | 01/23/2026 | 1097307026 | CMS |
| Novo Nordisk Inc | $32.27 | 09/16/2024 | Education | Undisputed | 01/23/2026 | 1097314258 | CMS |
| Novo Nordisk Inc | $32.27 | 09/16/2024 | Education | Undisputed | 01/23/2026 | 1097542476 | CMS |
| Novo Nordisk Inc | $32.27 | 09/16/2024 | Education | Undisputed | 01/23/2026 | 1097794344 | CMS |
| Rhythm Pharmaceuticals, Inc. | $25.44 | 03/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1141480818 | CMS |
| Rhythm Pharmaceuticals, Inc. | $20.27 | 05/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1141480820 | CMS |
| VIVUS LLC | $89.76 | 04/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1129415270 | CMS |
| VIVUS LLC | $3,750.00 | 05/09/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1129415272 | CMS |
| VIVUS LLC | $1,250.00 | 09/12/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1129415274 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.